IRWD

#2832
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
3.5 1 USD
-2.50%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
3.50
3.67
년간 변동
0.56
5.78
일일 변동
-2.50%
월간 변동
-16.03%
6달 변화
+1.15%
년간 변동율
+466.13%
이전 종가
3.6 0
Open
3.6 3
저가
3.5 0
High
3.6 7
양
247
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 577.79 M
  • Employee 100
  • Founded 1998
  • CEO N/A
  • Website www.ironwoodpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000GBZ3J2
  • Industry 전문의약품 및 제네릭 의약품 제조업체
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
22.47
주가매출액비율
1.85

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

뉴스